Role of biomarkers in antimicrobial stewardship: physicians’ perspectives

Biomarkers are playing an increasingly important role in antimicrobial stewardship. Their applications have included use in algorithms that evaluate suspected bacterial infections or provide guidance on when to start or stop antibiotic therapy, or when therapy should be repeated over a short period...

Full description

Saved in:
Bibliographic Details
Published inThe Korean journal of internal medicine Vol. 39; no. 3; pp. 413 - 429
Main Authors Hyeri Seok, Dae Won Park
Format Journal Article
LanguageKorean
Published 대한내과학회 31.05.2024
Subjects
Antimicrobial stewardship
Biomarkers
C-reactive protein
Presepsin protein
Procalcitonin
Online AccessGet full text

Cover

More Information
Summary:Biomarkers are playing an increasingly important role in antimicrobial stewardship. Their applications have included use in algorithms that evaluate suspected bacterial infections or provide guidance on when to start or stop antibiotic therapy, or when therapy should be repeated over a short period (6-12 h). Diseases in which biomarkers are used as complementary tools to determine the initiation of antibiotics include sepsis, lower respiratory tract infection (LRTI), COVID-19, acute heart failure, infectious endocarditis, acute coronary syndrome, and acute pancreatitis. In addition, cut-off values of biomarkers have been used to inform the decision to discontinue antibiotics for diseases such as sepsis, LRTI, and febrile neutropenia. The biomarkers used in antimicrobial stewardship include procalcitonin (PCT), C-reactive protein (CRP), presepsin, and interleukin (IL)-1β/IL-8. The cut-off values vary depending on the disease and study, with a range of 0.25-1.0 ng/mL for PCT and 8-50 mg/L for CRP. Biomarkers can complement clinical diagnosis, but further studies of microbiological biomarkers are needed to ensure appropriate antibiotic selection.
Bibliography:The Korean Association Of Internal Medicine
ISSN:1226-3303
2005-6648